https://endpts.com/fda-approves-junshi-coherus-pd-1-toripalimab-for-nasopharyngeal-carcinoma/
The first Chinese PD-1 is coming to the US market, as the FDA approves toripalimab in recurrent or metastatic nasopharyngeal carcinoma (NPC) across all lines of treatment. Junshi Biosciences — which back in 2018 became the first drugmaker to win approval in C…
Create an account
or login to join the discussion